PRNewsWire · JNJ · November 7, 2026

Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients

Get the app for more

Explore stock news, insights and company research.